Literature DB >> 32366435

Incidental Testicular Pathologies in Patients With Idiopathic Hydrocele Testis: Is Preoperative Scrotal Ultrasound Justified?

Mona Kafka1, Kilian Strohhacker1, Friedrich Aigner2, Fabian Steinkohl2, Wolfgang Horninger1, Renate Pichler1, Isabel Heidegger3.   

Abstract

BACKGROUND/AIM: Hydrocele testis is a common disease with a prevalence of 1% in adults. Although it can be diagnosed by physical examination, scrotal ultrasound represents a standard diagnostic tool, to exclude underlying pathologies among them testicular or scrotal malignancies. PATIENTS AND METHODS: We conducted a retrospective analysis of 156 patients aged between 20 and 60 years who underwent surgical hydrocelectomy between 2003 and 2018. Pre-surgical ultrasound, histological results, complications and patients' characteristics were analysed.
RESULTS: Malignancies were found in 0% of patients in the pre-surgical ultrasound. Interestingly, we found a higher incidence of hydrocele testis in patients with increasing age and 27% presented with symptoms other than painless enlargement of the scrotum. Among them recurrent pain was the most common. Surgical complications occurred in only 3.2%.
CONCLUSION: Testicular cancer is an important differential diagnosis of hydrocele testis. However, in our study no case of incidental testicular cancer or scrotal malignancy was found in the pre-surgical ultrasound. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Testicular cancer; hydrocele testis; scrotal malignancies; ultrasound

Mesh:

Year:  2020        PMID: 32366435     DOI: 10.21873/anticanres.14261

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Techniques - Mini-incision and plication (MIP) cure hydrocele: A minimally invasive surgical variation.

Authors:  Anthony Joe Nassour; Darius Ashrafi; Dinesh Patel
Journal:  Can Urol Assoc J       Date:  2022-05       Impact factor: 1.862

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.